Avillion names new CEO
This article was originally published in Scrip
Avillion, a drug development company focused on co-development and financing of late-stage pharmaceutical candidates from Phase III clinical development to marketing approval, has named Dr Allison Jeynes-Ellis chief executive officer. Dr Jeynes-Ellis is a founding member of Avillion's management team and was formerly the company's chief medical officer. She replaces Lewis Cameron who has "left the company to pursue other opportunities," Avillion said.
You may also be interested in...
In an exclusive interview, Barbara Lueckel, global head of research technologies at Roche Pharma Partnering, talks about the rationale behind the 2020 deals with Bicycle Therapeutics and Nimble Therapeutics. She gives insight into how deal makers are shifting gears to make deals happen in the challenging environment of the global coronavirus pandemic.
As the COVID-19 pandemic escalates, companies across the world are preparing to roll out commercial test kits for the detection of SARS-CoV-2.
Biopharmaceutical companies doubled-down on rare disease treatments during the last five years, thanks to a potent combination of scientific discovery and appealing business incentives.